NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free ACOR Stock Alerts $13.21 +1.30 (+10.91%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.82▼$13.3250-Day Range$11.91▼$17.5052-Week Range$8.98▼$24.20Volume4,531 shsAverage Volume3,814 shsMarket Capitalization$16.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Acorda Therapeutics alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Acorda Therapeutics Stock (NASDAQ:ACOR)Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More ACOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACOR Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comAcorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.comMarch 26, 2024 | finance.yahoo.comAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Acorda Therapeutics (NASDAQ:ACOR)March 18, 2024 | americanbankingnews.comAcorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest UpdateMarch 11, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryFebruary 28, 2024 | stocknews.com3 Biotech Stocks to Watch in March for SuccessFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 22, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesFebruary 20, 2024 | msn.comAcorda: No policy vs. TikTok use in PNPFebruary 6, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeFebruary 5, 2024 | msn.comTeodoro, Acorda nix Mindanao separation from PhilippinesJanuary 31, 2024 | msn.comPNP chief Acorda tells ranks: Ignore ‘political noise’January 29, 2024 | finance.yahoo.comDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - TechnavioJanuary 11, 2024 | markets.businessinsider.comAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAJanuary 10, 2024 | stocknews.com3 Biotech Stocks to Keep an Eye on in 2024January 8, 2024 | msn.comAcorda files raps vs person spreading false info in viral vlogJanuary 8, 2024 | msn.comAcorda slams vlogger in 'disinformation' driveJanuary 8, 2024 | msn.comAcorda files cybercrime raps vs person spreading false info in a vlogJanuary 7, 2024 | msn.comAcorda eyes Pinoy apps vs cybercrimesJanuary 6, 2024 | morningstar.comAcorda Therapeutics Inc ACORJanuary 4, 2024 | finance.yahoo.comAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical OperationsDecember 18, 2023 | stocknews.comModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?December 18, 2023 | finance.yahoo.comAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The IndustryDecember 15, 2023 | stocknews.com3 Biotech Stocks Flashing Year-End 'Buy' Signals"November 24, 2023 | stocknews.com3 Safe Biotech Stocks to Buy This WeekSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Confirmed)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($17.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,920,000.00 Net Margins-14.35% Pretax Margin-16.72% Return on Equity-21.45% Return on Assets-4.25% Debt Debt-to-Equity Ratio3.07 Current Ratio1.59 Quick Ratio1.21 Sales & Book Value Annual Sales$118.57 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value$77.13 per share Price / Book0.15Miscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$14.77 million OptionableNo Data Beta1.41 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSInhibikase TherapeuticsNYSE:IKTEvaxion Biotech A/SNASDAQ:EVAXSenti BiosciencesNASDAQ:SNTIBioCardiaNASDAQ:BCDAView All Competitors ACOR Stock Analysis - Frequently Asked Questions How have ACOR shares performed in 2024? Acorda Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, ACOR stock has decreased by 12.5% and is now trading at $13.21. View the best growth stocks for 2024 here. Are investors shorting Acorda Therapeutics? Acorda Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 9,500 shares, a drop of 14.4% from the February 29th total of 11,100 shares. Based on an average daily volume of 3,800 shares, the short-interest ratio is currently 2.5 days. Approximately 0.8% of the company's shares are sold short. View Acorda Therapeutics' Short Interest. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our ACOR earnings forecast. How can I listen to Acorda Therapeutics' earnings call? Acorda Therapeutics will be holding an earnings conference call on Monday, April 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "732092". How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, beating analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative net margin of 14.35% and a negative trailing twelve-month return on equity of 21.45%. When did Acorda Therapeutics' stock split? Acorda Therapeutics shares reverse split on the morning of Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Acorda Therapeutics? Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACOR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.